iXensor Co., Ltd.
iXensor Co., Ltd. provides technology platform that turns smartphones into medical diagnostic devices through its smart color sensing technology for connected healthcare. It offers PixoTest Vision Analysis System(lipid), and PixoHealth Vision(app) for chronic disease; and Eveline Smart Fertility System and Eveline Care Telehealth Platform for women's health management. The company was founded in … Read more
iXensor Co., Ltd. (6734) - Net Assets
Latest net assets as of June 2025: NT$-16.17 Million TWD
Based on the latest financial reports, iXensor Co., Ltd. (6734) has net assets worth NT$-16.17 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$44.38 Million) and total liabilities (NT$60.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$-16.17 Million |
| % of Total Assets | -36.43% |
| Annual Growth Rate | -42.02% |
| 5-Year Change | -87.29% |
| 10-Year Change | N/A |
| Growth Volatility | 39.61 |
iXensor Co., Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how iXensor Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for iXensor Co., Ltd. (2019–2024)
The table below shows the annual net assets of iXensor Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$10.05 Million | -69.29% |
| 2023-12-31 | NT$32.73 Million | -59.43% |
| 2022-12-31 | NT$80.69 Million | +41.58% |
| 2021-12-31 | NT$56.99 Million | -27.94% |
| 2020-12-31 | NT$79.09 Million | -48.49% |
| 2019-12-31 | NT$153.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to iXensor Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6456100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$306.23 Million | 3046.48% |
| Other Comprehensive Income | NT$7.08 Million | 70.43% |
| Other Components | NT$112.92 Million | 1123.39% |
| Total Equity | NT$10.05 Million | 100.00% |
iXensor Co., Ltd. Competitors by Market Cap
The table below lists competitors of iXensor Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tertiary Minerals plc
PINK:TTIRF
|
$4.11 Million |
|
Norditek Group AB
ST:NOTEK
|
$4.11 Million |
|
R. S. Software (India) Limited
NSE:RSSOFTWARE
|
$4.11 Million |
|
Geratherm Medical AG
XETRA:GME
|
$4.11 Million |
|
Reach Resources Ltd
AU:RR1
|
$4.11 Million |
|
Nxu Inc.
NYSE:NXU
|
$4.11 Million |
|
Synergy House Berhad
KLSE:0279
|
$4.11 Million |
|
Terra Uranium Ltd
AU:T92
|
$4.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in iXensor Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 32,733,000 to 10,052,000, a change of -22,681,000 (-69.3%).
- Net loss of 46,808,000 reduced equity.
- New share issuances of 24,075,000 increased equity.
- Other comprehensive income decreased equity by 7,764,000.
- Other factors increased equity by 7,816,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-46.81 Million | -465.66% |
| Share Issuances | NT$24.07 Million | +239.5% |
| Other Comprehensive Income | NT$-7.76 Million | -77.24% |
| Other Changes | NT$7.82 Million | +77.76% |
| Total Change | NT$- | -69.29% |
Book Value vs Market Value Analysis
This analysis compares iXensor Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.51x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.03x to 14.51x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$3.15 | NT$6.40 | x |
| 2020-12-31 | NT$1.60 | NT$6.40 | x |
| 2021-12-31 | NT$1.09 | NT$6.40 | x |
| 2022-12-31 | NT$1.49 | NT$6.40 | x |
| 2023-12-31 | NT$0.60 | NT$6.40 | x |
| 2024-12-31 | NT$0.44 | NT$6.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently iXensor Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -465.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -240.55%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 7.42x
- Recent ROE (-465.66%) is below the historical average (-159.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -68.16% | -348.47% | 0.17x | 1.17x | NT$-120.01 Million |
| 2020 | -96.87% | -481.12% | 0.16x | 1.23x | NT$-84.52 Million |
| 2021 | -128.23% | -294.75% | 0.34x | 1.29x | NT$-78.78 Million |
| 2022 | -6.06% | -4.65% | 1.00x | 1.30x | NT$-12.96 Million |
| 2023 | -193.05% | -302.51% | 0.22x | 2.94x | NT$-66.47 Million |
| 2024 | -465.66% | -240.55% | 0.26x | 7.42x | NT$-47.81 Million |
Industry Comparison
This section compares iXensor Co., Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,188,209,400
- Average return on equity (ROE) among peers: 10.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| iXensor Co., Ltd. (6734) | NT$-16.17 Million | -68.16% | N/A | $4.11 Million |
| Health & Life Co., Ltd. (1781) | $393.05 Million | 6.17% | 1.08x | $12.92 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.76 Million |
| Wellell Inc (4106) | $458.47 Million | 22.17% | 0.32x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.66 Billion | 8.16% | 1.02x | $34.41 Million |
| United Orthopedic (4129) | $2.22 Billion | 5.87% | 0.94x | $279.97 Million |
| Dynamic Medical Technologies (4138) | $1.70 Billion | 12.34% | 0.81x | $39.16 Million |
| Ok Biotech Co Ltd (4155) | $452.10 Million | 21.38% | 0.72x | $44.61 Million |
| Bioptik Technology (4161) | $824.15 Million | 10.40% | 0.82x | $30.48 Million |
| EPS Bio Technology Corp. (4183) | $304.55 Million | 5.68% | 0.78x | $4.27 Million |